摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[5-[2(S)-(2,4-dichloro-5-methoxy-phenoxy)-propionamido]-2,5-dideoxy-2-fluoro-β-D-arabino-furanosyl]-5-ethyluracil | 187588-73-4

中文名称
——
中文别名
——
英文名称
1-[5-[2(S)-(2,4-dichloro-5-methoxy-phenoxy)-propionamido]-2,5-dideoxy-2-fluoro-β-D-arabino-furanosyl]-5-ethyluracil
英文别名
(2S)-2-(2,4-dichloro-5-methoxy-phenoxy)-N-[[(2R,3R,4S,5R)-5-(5-ethyl-2,4-dioxo-pyrimidin-1-yl)-4-fluoro-3-hydroxy-tetrahydrofuran-2-yl]methyl]propanamide;(2S)-2-(2,4-dichloro-5-methoxyphenoxy)-N-[[(2R,3R,4S,5R)-5-(5-ethyl-2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methyl]propanamide
1-[5-[2(S)-(2,4-dichloro-5-methoxy-phenoxy)-propionamido]-2,5-dideoxy-2-fluoro-β-D-arabino-furanosyl]-5-ethyluracil化学式
CAS
187588-73-4
化学式
C21H24Cl2FN3O7
mdl
——
分子量
520.342
InChiKey
NQXYZAIBCVSURW-KZEOBUNESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    34
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    126
  • 氢给体数:
    3
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    1-(5-amino-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyluracil 、 (S)-2-(2,4-dichloro-5-methoxyphenoxy)-propionic acid 、 草酰氯氮气 、 crude product 、 甲醇 作用下, 以 甲苯N,N-二甲基甲酰胺sodium hydroxide 为溶剂, 反应 1.17h, 以to give 33.1 g (69.7%) of 1-[5-[2(S)-(2,4-dichloro-5-methoxyphenoxy)propionamido]-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl]-5-ethyluracil as a white crystalline solid, m.p. 195°-196° C.的产率得到1-[5-[2(S)-(2,4-dichloro-5-methoxy-phenoxy)-propionamido]-2,5-dideoxy-2-fluoro-β-D-arabino-furanosyl]-5-ethyluracil
    参考文献:
    名称:
    3'-O-aminoacyl ARA uridines, method of making, and antiviral activity
    摘要:
    公开了式子为##STR1##的嘧啶核苷衍生物,其中R.sup.1代表芳基,R.sup.2代表较低的烷基,R.sup.3代表从氨基酸衍生的酰基基团,R.sup.4代表氢或氟,星号表示所指示的碳原子的构型为(S)或(R)。这些化合物及其盐可用作抗病毒剂。
    公开号:
    US05705492A1
点击查看最新优质反应信息

文献信息

  • Pyrimidine nucleosides and methods for treating viral infections with
    申请人:Hoffmann-La Roche Inc.
    公开号:US05698532A1
    公开(公告)日:1997-12-16
    This invention is directed to the novel pyrimidine derivative 1-\x9b5-\x9b2(S)-(2,4-dichloro-5-methoxyphenoxy) propionamido!-2,5-dideoxy-2-fluoro-.beta.-D-arabinofuranosly!-5-ethyluraci l and its use as an antiviral agent, as well as to intermediates useful in the synthesis of this compound.
    本发明涉及新型嘧啶衍生物1-\x9b5-\x9b2(S)-(2,4-二氯-5-甲氧基苯氧基)丙酰胺基!-2,5-二脱氧-2-氟-β-D-阿拉伯核糖基!-5-乙基尿嘧啶及其作为抗病毒剂的用途,以及在合成该化合物过程中有用的中间体。
  • [EN] PYRIMIDINE NUCLEOSIDE DERIVATIVE<br/>[FR] DERIVE NUCLEOSIDE DE PYRIMIDINE
    申请人:F. HOFFMANN-LA ROCHE AG
    公开号:WO1997003083A1
    公开(公告)日:1997-01-30
    (EN) 1-[5-[2(S)-(2,4-Dichloro-5-methoxyphenoxy)propionamido]-2,5-dideoxy-2-fluoro-$g(b)-D-arabinofuranosyl]-5-ethyluracil of formula (I) is an antiviral agent with high oral bioavailability.(FR) Le 1-[5-[2(S)-(2,4-dichloro-5-méthoxyphénoxy)propionamido]-2,5-didésoxy-2-fluoro-$g(b)-D-arabinofuranosyl]-5-éthyluracile de formule (I) est un agent antiviral présentant une biodisponibilité élevée.
    1-[5-[2(S)-(2,4-二氯-5-甲氧基苯氧基)乙酸氨酰胺]-2,5-脱氧-2-氟-γ(b)-D-葡萄糖尿苷酰基]-5-ethyl尿苷的分子式为(I),是一种高口服生物利用度的抗病毒药物。
  • PYRIMIDINE NUCLEOSIDE DERIVATIVES
    申请人:F. HOFFMANN-LA ROCHE AG
    公开号:EP0850246B1
    公开(公告)日:2001-11-14
  • PYRIMIDINE NUCLEOSIDE DERIVATIVE
    申请人:F. HOFFMANN-LA ROCHE AG
    公开号:EP0850247A1
    公开(公告)日:1998-07-01
  • [EN] PYRIMIDINE NUCLEOSIDE DERIVATIVES<br/>[FR] DERIVES NUCLEOSIDIQUES DE PYRIMIDINE
    申请人:——
    公开号:WO1997003082A2
    公开(公告)日:1997-01-30
    [EN] Compounds of formula (I), wherein R<1> represents aryl, R<2> represents lower alkyl, R<3> represents an acyl group derived from an amino acid and R<4> represents hydrogen or fluorine and the asterisk denotes that the configuration at the carbon atom indicated thereby is (S) or (R), and pharmaceutically acceptable acid addition salts thereof are antiviral agents.
    [FR] Composés de formule (I) dans laquelle R<1> représente aryle, R<2> représente alkyle inférieur, R<3> représente un groupe acyle dérivé d'un acide aminé et R<4> représente hydrogène ou fluor, l'astérisque signifiant que la configuration de l'atome de carbone ainsi indiqué est (S) ou (R), et sels d'addition d'acide pharmaceutiquement acceptables desdits composés, utiles en tant qu'agents antiviraux.
查看更多

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 1-citosin-1-yl-1,2,5-trideoxy-α-L-threo-pentofuranos-4-yloxymethylphosphonic acid 9-[2,5-dideoxy-2-fluoro-5-[N-(N-2-hydroxybenzoyl)sulfamoyl]amino-β-D-ribofuranosyl]adenine triethylammonium salt 5'-amino-2',5'-dideoxy-2'-fuorouridine 1-(5'-deoxythymidin-5'-yl)-4-[methyloxycarbonyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(cyclohexylacetamido)adenosine 2',5'-dideoxy-2'-(3'',5''-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine 2',5'-dideoxy-5'-(hydroxyethylthio)adenosine 1-(5-azido-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyluracil 1-(5'-deoxythymidin-5'-yl)-4-[methyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 4′-C-azidomethyl-2′-deoxy-2′-fluorouridine 2',5'-dideoxy-6-thioguanosine thymidylyl (3'-5') 5'-seleno-5'-deoxythymidine 3'-O-(t-butyldimethylsilyl)-4'-α-methylthymidine (E)- and (Z)-5-(2-bromovinyl)-1-(5-chloro-2,5-dideoxy-β-D-erythro-pentofuranosyl)-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>succinamic acid N-butyl-N'-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranose-5-yl>maleamide N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>maleamic acid 4'-chloromethyl-2'-deoxy-2',2'-difluorocytidine 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-(L-valinyl)cytidine dihydrochloride 5'-deoxy-5'-{4-[2-(3-oxo-3H-benzo[f]chromen-1-yl)acetamidomethyl]-1H-1,2,3-triazol-1-yl}thymidine N6-benzoyl-3'-O-t-butyldimethylsilyl-5'-sulfamoylazido-2',5'-dideoxyadenosine N-{9-[(2R,4S,5R)-5-(Acetylamino-methyl)-4-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide